Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
REGN7257 for Severe Aplastic Anemia
Recruiting1 awardPhase 1 & 2
Cleveland, Ohio
This trial is assessing the safety and efficacy of REGN7257 in patients with severe aplastic anemia who are refractory or have relapsed after immunosuppressive therapy.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.